New combo therapy aims to shrink inoperable esophageal tumors

NCT ID NCT06452602

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated Jun 15, 2026 · Updated 15 times

Summary

This study tests a two-step approach for people with advanced esophageal cancer that cannot be removed by surgery. First, patients receive a combination of immunotherapy and chemotherapy. Then, based on how well the tumor responds, they get either the same drugs plus radiation or a different chemotherapy with radiation. The goal is to see if this personalized plan can help patients live longer without their cancer growing. The trial is currently recruiting 60 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Cancer Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER